PLAT

(redirected from tissue-type plasminogen activator)
Also found in: Dictionary, Thesaurus, Legal, Financial, Encyclopedia.

PLAT

A gene on chromosome 8p12 that encodes tissue plasminogen activator, which converts inactive plasminogen to plasmin by hydrolysing a single Arg-Val bond in plasminogen, thereby playing a key role in tissue remodelling, degradation, cell migration and other cellular events. PLAT directly facilitates neuronal migration.
References in periodicals archive ?
The plasma concentration of fibrinogen, tissue-type plasminogen activator (tPA) and plasminogen activator inhibitor (PAI-1) were measured by standard sandwich ELISA technique using commercial kits (Diagnostica STAGO, R.
An endothelial storage granule for tissue-type plasminogen activator.
The production of improved tissue-type plasminogen activator in Escherichia coli.
Molecular forms of plasminogen activator inhibitor-1 (PAI-1) and tissue-type plasminogen activator (t-PA) in human plasma.
Blood collection and handling procedures for assessment of tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor-1 (PAI-1).
Of the two plasminogen activators known, tissue-type plasminogen activator is involved mainly in intravascular fibrinolysis, whereas urokinase plasminogen activator (uPA)5 is most important in pericellular matrix degradation processes, such as in wound healing, inflammatory disease, and cancer invasion (1, 2).
In one clinical study, low tissue-type plasminogen activator activity and higher PAI-1 concentrations were observed in survivors of myocardial infarction compared with healthy age-matched controls (58).
The fibrinolytic activity of blood depends on the balance between the circulating concentrations of tissue-type plasminogen activator (t-PA) (4) and plasminogen activator inhibitor type 1 (PAI-1), which are both secreted by endothelial cells [2].
A sensitive and robust assay for urokinase and tissue-type plasminogen activators (uPA and tPA) and their inhibitor type I (PAI-1) in breast tumor cytosols.
Clinical relevance of the urokinase-type and tissue-type plasminogen activators and their type 1 inhibitor in breast cancer.